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Meta-signature of human 
endometrial receptivity: a meta-
analysis and validation study of 
transcriptomic biomarkers
Signe Altmäe  1,2,3, Mariann Koel2,4,5, Urmo Võsa6, Priit Adler7, Marina Suhorutšenko2,8, 
Triin Laisk-Podar2,8, Viktorija Kukushkina2, Merli Saare2,8, Agne Velthut-Meikas2, Kaarel 
Krjutškov2,4, Lusine Aghajanova9, Parameswaran G. Lalitkumar1, Kristina Gemzell-
Danielsson1, Linda Giudice9, Carlos Simón10 & Andres Salumets2,8,11
Previous transcriptome studies of the human endometrium have revealed hundreds of simultaneously 
up- and down-regulated genes that are involved in endometrial receptivity. However, the overlap 
between the studies is relatively small, and we are still searching for potential diagnostic biomarkers. 
Here we perform a meta-analysis of endometrial-receptivity associated genes on 164 endometrial 
samples (76 from ‘pre-receptive’ and 88 from mid-secretory, ‘receptive’ phase endometria) using a 
robust rank aggregation (RRA) method, followed by enrichment analysis, and regulatory microRNA 
prediction. We identify a meta-signature of endometrial receptivity involving 57 mRNA genes as 
putative receptivity markers, where 39 of these we confirm experimentally using RNA-sequencing 
method in two separate datasets. The meta-signature genes highlight the importance of immune 
responses, the complement cascade pathway and the involvement of exosomes in mid-secretory 
endometrial functions. Bioinformatic prediction identifies 348 microRNAs that could regulate 30 
endometrial-receptivity associated genes, and we confirm experimentally the decreased expression of 
19 microRNAs with 11 corresponding up-regulated meta-signature genes in our validation experiments. 
The 57 identified meta-signature genes and involved pathways, together with their regulatory 
microRNAs could serve as promising and sought-after biomarkers of endometrial receptivity, fertility 
and infertility.
The period of endometrial receptivity, also known as the window of implantation (WOI), is the limited time 
(one to two days) when luminal epithelium is favourable for embryo adhesion as the first step of implantation1. 
Successful embryo implantation depends on synchronization of a viable embryo and receptive endometrium. 
In fact, inadequate uterine receptivity has been estimated to contribute to one third of implantation failures, 
whereas the embryo itself is responsible for two thirds of them2, 3. In assisted reproductive technologies where 
good-quality embryos are transferred as a standard of care, implantation failure remains an unsolved obstacle4–6. 
In patients with recurrent implantation failure (RIF) temporal displacement of the WOI has been described in 
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one out of four patients7, thus suggesting the possibility of these women suffering RIF of endometrial origin. 
Further, impaired decidualization of endometrial stromal cells that predisposes to late implantation may negate 
endometrial ‘embryo quality control’ and cause early pregnancy failure8–10. Hence, better understanding of endo-
metrial receptivity and the importance of the mechanisms involved in mid-secretory endometrial functions is 
warranted.
From the first histological dating methods11, 12 to the new ‘omics’ technologies, extensive efforts have been 
made to understand and characterise receptive endometrium. Traditional endometrial dating criteria, like tissue 
histology, are obsolete, since their accuracy, reproducibility and functional relevance have been questioned in 
various randomised studies13, 14. This has encouraged further investigation and application of new technologies to 
diagnose endometrial receptivity objectively, since reliable diagnostic markers are still lacking and the molecular 
mechanisms remain largely unclear15–17.
With the ‘omics’ revolution, the quest for the transcriptomic signature of human endometrial receptivity has 
revealed hundreds of simultaneously up- and down-regulated genes implicated in the phenomenon (reviewed 
in ref. 18). While any given study yields a number of genes, the overlap between different studies is relatively 
small. The perceived limitations of this technology have been well defined and lie in differences in experimental 
design, timing and conditions of endometrial sampling, selection criteria regarding patients, transcriptome array/
sequencing platforms and genome annotation versions used, pipelines for data processing and a lack of consistent 
standards for data presentation19–23.
To overcome the aforementioned limitations in endometrial transcriptome analyses, we applied a recently 
published robust rank aggregation (RRA) method24, followed by enrichment analysis, to identify a meta-signature 
or consensus signature of highly putative biomarkers of endometrial receptivity. Additionally, we set up to ana-
lyse possible microRNAs that could influence the endometrial receptivity-associated genes/mRNAs. Further, we 
aimed to experimentally validate the meta-signature mRNA genes and their regulatory miRNAs in two independ-
ent sample sets.
Results
Identification of relevant studies. The search process and results of the systematic literature review are 
presented in detail in Supplementary Figure 1. Eventually, out of 57 eligible publications, 14 remained suitable 
for qualitative analysis. Five eligible studies25–29 were not included in the final analysis, since the data on lists of 
differentially expressed genes were not available publicly nor in response to requests to the authors. A detailed 
description of the studies included in the final analysis is presented in Table 1. Our pooled dataset obtained from 
the nine remaining studies covered 76 ‘pre-receptive’-phase (28 biopsy samples from the proliferative phase and 
48 from the early secretory phase) and 88 mid-secretory, ‘receptive’ phase endometrial samples.
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Table 1. Characteristics of the analysed datasets. ES indicates early secretory phase, MS – mid-secretory 
phase, cd – cycle day, LH – luteinizing hormone, FC – fold change, N/S – not specified, * – samples pooled for 
microarray analysis, ** – ERA test training that was performed on 68 additional endometrial samples.
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Meta-signature of endometrial receptivity-associated genes. Using robust rank aggregation anal-
ysis, we identified a statistically significant meta-signature of 52 up-regulated and five down-regulated genes in 
mid-secretory vs. ‘pre-receptive’ endometrium (see Table 2). The up-regulated transcripts with the highest scores 
in receptive-phase endometrium were PAEP, SPP1, GPX3, MAOA and GADD45A. The five down-regulated tran-
scripts identified as receptivity-associated genes were SFRP4, EDN3, OLFM1, CRABP2 and MMP7.
Enrichment analyses. We used up-to-date enrichment analysis software (g:Profiler) for analysis of bio-
logical processes and pathways connected to the meta-signature of mid-secretory endometrium. A significant 
proportion of the genes were involved in biological processes such as responses to external stimuli, responses 
to wounding, inflammatory responses, negative regulation of coagulation, humoral immune responses, and 
immunoglobulin-mediated immune responses, among others. Fig. 1 and Supplementary Table 1 show the con-
nections of the 57 endometrial receptivity genes with their respective Gene Ontology biological processes. The 
only significantly enriched pathway related to the meta-signature genes was a KEGG pathway of complement and 
coagulation cascades, where the identified genes were connected to the complement cascade part (p = 0.00112) 
(see Fig. 2). A significant number of the genes were also connected with the extracellular region and exosomes. 
In order to confirm the involvement of exosomes, we searched for the presence of the meta-signature genes in 
human exosomes based on the exosome database, ExoCarta (exocarta.org). Fisher’s Exact Test was performed to 
analyse if meta-signature genes were over represented in the exosome database. All the human protein coding 
genes were downloading from ENSEMBL v75 database (version February 2014) and mRNAs or proteins from 
Exocarta database (exocarta.org). Altogether, meta-signature genes had 2.13 times higher probability to be in 
the exosomes than the rest of the protein-coding genes in the human genome (Fisher’s exact test, two-sided 
p = 0.0059). The 28 identified proteins from the meta-signature gene list that have been shown to be in exosomes 
are presented in Fig. 3 that illustrates the involvement of extracellular vesicles (exosomes and microvesicles) in 
embryo implantation process.
Validation of meta-signature genes in two independent sample sets. Meta-analysis identified 57 
genes differentially expressed between the ‘pre-receptive’ and mid-secretory endometrium, where 52 genes were 
up- and five were down-regulated at WOI. Our RNA-sequencing (RNA-seq) analysis on 20 independent endo-
metrial biopsy samples from fertile women confirmed the differential expression of 52 meta-signature genes (all 
of them with fold change of ≥3) – 48 of these genes were likewise up-regulated and four were down-regulated 
(CRABP2, EDN3, OLFM1, SFRP4) in the mid-secretory endometria (Fig. 4). MMP7 and CFD were not differ-
entially expressed in our RNA-seq analysis of LH+8 vs. LH+2 phase endometria. Three genes, COMP, MT1H, 
S100P, did not pass the initial filtering of RNA-seq data (counts per million, CPM > 2 in at least 15 samples), 
which might be due to their low expression levels. The filtering was applied to rule out transcripts with very low 
or inconsistent expression levels across individuals.
Next, we investigated the expression of the 57 meta-signature genes in FACS (fluorescence-activated cell sort-
ing)-sorted endometrial epithelial and stromal cells from two time points in the menstrual cycle, early secretory 
vs. mid-secretory phase, from 16 fertile women. Thirty-nine of those genes were significantly up-regulated and 
four were down-regulated (CRABP2, EDN3, OLFM1, SFRP4) in the receptive phase in those cell populations (all 
of them with fold change of ≥2) (Fig. 4; Supplementary Figure 2). Although most of the genes were up-regulated 
in both cell types, it is notable that the expression of ANXA2, COMP, CP, DDX52, DPP4, DYNLT3, EDNRB, 
EFNA1, G0S2, HABP2, LAMB3, MAOA, NDRG1, PRUNE2, SPP1, and TSPAN8 was epithelium-specific (Fig. 5), 
while none of the genes was down-regulated in the epithelial cells only. The stroma-specific up-regulated genes 
were APOD, CFD, C1R and DKK1, and down-regulated gene was OLFM1 (Fig. 5). It is noteworthy that although 
most of the genes were up-regulated in both cell types, the expression of these genes was still higher in the epi-
thelial cells.
Further validation of these confirmed meta-signature genes was carried out with real-time PCR. Up-regulation 
of DDX52, DYNLT3, C1R and APOD expression levels in the receptive phase endometrial samples was confirmed 
(Supplementary Figure 3). Furthermore, the cell-specific up-regulated DDX52 and DYNLT3 expression was con-
firmed in FACS-sorted epithelial cells, and the stromal cell-specific C1R and APOD up-regulation was confirmed 
in the FACS-sorted stromal cells (Supplementary Figure 3).
In conclusion, the validation of the 57 meta-analysis consensus genes of the receptive phase endometrium 
among the two independent sets of endometrial tissue samples and cell-populations analysed confirmed the dif-
ferential expression of 39 genes, with 35 up- and 4 down-regulated expression during WOI (Fig. 4).
In silico analysis of potential microRNAs regulating meta-signature genes. To evaluate the 
potential regulation of the 57 meta-signature genes, we predicted their putative regulatory-microRNAs using 
three different in silico target prediction algorithms. DIANA microT-CDS predicted 1,355 microRNAs with 
12,627 potential binding sites, TargetScan 7.0 predicted 2,521 microRNAs with 32,560 potential binding sites, 
and miRanda predicted 2,568 microRNAs with 42,413 potential binding sites. The overlap between all three 
algorithms resulted in 818 microRNAs and 1,403 potential unique binding sites for 43 meta-signature genes 
(Supplementary Table 2).
To add an additional filter to the bioinformatic predictions, we overlaid those with experimentally determined 
Argonaute binding sites (microRNAs regulate gene expression by guiding Argonaute proteins to specific target 
mRNA sequences), mined from publicly available AGO-CLIP datasets. Out of 1,403 intersected potential binding 
sites, 395 showed overlap with experimentally determined Argonaute binding site in human cell lines, filtering 
down to the most probable microRNA and mRNA interactions. These 395 sites included interactions between 30 
genes from our original meta-signature gene list and 348 microRNAs (Supplementary Table 3).
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ENTREZ 
ID HUGO Symbol HUGO Name VAL* VAL** RRA score Adjusted P
5047 PAEPb,c,d,e Progestagen-associated endometrial protein 90 7.68E-18 2.99E-13
6696 SPP1b,d,e Secreted phosphoprotein 1 (osteopontin) 30, 32, 87, 89, 91 92 2.06E-15 8.04E-11
2878 GPX3b,c,d,e Glutathione peroxidase 3 30, 86, 88, 91 1.89E-14 7.40E-10
4128 MAOAa,b,d,e Monoamine oxidase A 17 93 + 2.32E-13 9.04E-09
1647 GADD45Ab,c,d,e Growth arrest and DNA-damage-inducible, alpha 2.73E-13 1.06E-08
22943 DKK1a,b,d,e Dickkopf WNT signalling pathway inhibitor 1 17, 33, 85 94 2.80E-13 1.09E-08
1364 CLDN4a,b,d,e Claudin 4 87, 88 87, 95 9.14E-13 3.57E-08
722 C4BPAb,d,e Complement component 4 binding protein, alpha 91 56 1.60E-12 6.23E-08
3600 IL15a,b,d,e Interleukin 15 96 3.36E-12 1.31E-07
1604 CD55a,b,d,e CD55 molecule, decay accelerating factor for complement 33 97 5.47E-12 2.14E-07
3400 ID4b Inhibitor of DNA binding 4, dominant negative helix-loop-helix protein 6.43E-12 2.51E-07
10578 GNLYb,d Granulysin 98+ 1.78E-11 6.96E-07
1356 CPa,b,d Ceruloplasmin 2.81E-11 1.10E-06
6505 SLC1A1a,d,e Solute carrier family 1, member 1 88 5.27E-11 2.06E-06
1803 DPP4b,c,d,e Dipeptidyl-peptidase 4 32 99, 100 7.44E-11 2.90E-06
6947 TCN1d,e Transcobalamin I 1.54E-10 6.03E-06
1675 CFDa,b,d Complement factor D 2.56E-10 9.99E-06
307 ANXA4a,b,d,e Annexin A4 17, 89, 91 101 1.50E-09 5.85E-05
1942 EFNA1d Ephrin-A1 102 1.55E-09 6.06E-05
2634 GBP2a,b,d Guanylate binding protein 2, interferon-inducible 1.63E-09 6.38E-05
347 APODb,d,e Apolipoprotein D 85, 91 103 3.05E-09 1.19E-04
604 BCL6a,d B-cell CLL/lymphoma 6 104 4.42E-09 1.72E-04
1052 CEBPDd CCAAT/enhancer binding protein, delta 105 5.09E-09 1.99E-04
36 ACADSBe Acyl-CoA dehydrogenase, short/branched chain 6.16E-09 2.40E-04
11067 C10orf10a,d Chromosome 10 open reading frame 10 7.24E-09 2.83E-04
8714 ABCC3a,d,e ATP-binding cassette, sub-family C, member 3 7.53E-09 2.94E-04
4495 MT1Gb,d,e Metallothionein 1G 30, 38, 86 8.16E-09 3.19E-04
384 ARG2a,d Arginase 2 106 8.52E-09 3.33E-04
1311 COMPb,d,e Cartilage oligomeric matrix protein 32 9.02E-09 3.52E-04
50486 G0S2b,e G0/G1 switch 2 1.10E-08 4.31E-04
7103 TSPAN8a,d,e Tetraspanin 8 1.22E-08 4.76E-04
1672 DEFB1a,d Defensin, beta 1 107 1.43E-08 5.57E-04
4217 MAP3K5b,d,e Mitogen-activated protein kinase kinase kinase 5 1.54E-08 6.00E-04
1910 EDNRBc,d,e Endothelin receptor type B 108+ 2.34E-08 9.15E-04
158471 PRUNE2b Prune homolog 2 3.48E-08 1.36E-03
6286 S100Pa,b,d,e S100 calcium binding protein P 17, 28 25, 28 4.01E-08 1.56E-03
3484 IGFBP1e Insulin-like growth factor binding protein 1 33, 85 109 4.92E-08 1.92E-03
11056 DDX52 DEAD (Asp-Glu-Ala-Asp) box polypeptide 52 5.97E-08 2.33E-03
710 SERPING1a,b,d Serpin peptidase inhibitor, clade G, member 1 7.05E-08 2.75E-03
84159 ARID5Bd,e AT rich interactive domain 5B 8.69E-08 3.40E-03
3914 LAMB3b,d,e Laminin, beta 3 26 1.45E-07 5.66E-03
316 AOX1a,d,e Aldehyde oxidase 1 91 2.09E-07 8.17E-03
3620 IDO1 Indoleamine 2,3-dioxygenase 1 110 2.67E-07 1.04E-02
302 ANXA2b,e Annexin A2 111 3.26E-07 1.27E-02
3026 HABP2c,d,e Hyaluronan binding protein 2 112 3.26E-07 1.27E-02
715 C1Rb,e Complement component 1, r subcomponent 3.26E-07 1.27E-02
360 AQP3e Aquaporin 3 113 4.27E-07 1.66E-02
6990 DYNLT3a Dynein, light chain, Tctex-type 3 5.07E-07 1.98E-02
4496 MT1Hd,e Metallothionein 1 H 114 8.16E-07 3.18E-02
4837 NNMTd Nicotinamide N-methyltransferase 91 8.74E-07 3.41E-02
Continued
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ENTREZ 
ID HUGO Symbol HUGO Name VAL* VAL** RRA score Adjusted P
10397 NDRG1d N-myc downstream regulated 1 115 1.01E-06 3.95E-02
2028 ENPEP Glutamyl aminopeptidase 1.11E-06 4.32E-02
6424 SFRP4↓b Secreted frizzled-related protein 4 17 5.95E-11 2.32E-06
1908 EDN3↓b Endothelin 3 108+ 3.06E-10 1.20E-05
10439 OLFM1↓a,b Olfactomedin 1 116 1.65E-09 6.46E-05
1382 CRABP2↓a,b Cellular retinoic acid binding protein 2 56 1.97E-08 7.68E-04
4316 MMP7↓a,b Matrix metallopeptidase 7 4.07E-07 1.59E-02
Table 2. List of genes identified as specific biomarkers of mid-secretory endometrium when assessed in 
comparative transcriptome analyses with proliferative and early secretory endometrium in nine datasets. 52 
genes are up-regulated in mid-secretory endometrium, while five are down-regulated (↓). Genes validated in 
our independent sample sets of endometrial samples at LH+2 vs. LH+8 from healthy fertile women analysed 
with RNA-seq and cell type-specific RNA-seq methods are highlighted in bold. Genes present in the ERA 
diagnostic tool are underlined. Genes also identified in previous data-mining/review studies are indicated in 
super-scripts: a17, b31, c19, d29, and e32. VAL* indicates mRNA validation experiments in previous transcriptomic 
studies on mid-secretory endometrium using real-time PCR, Northern blot or in situ hybridisation analyses. 
VAL** indicates protein validation analyses in mid-secretory endometrium. + stands for validation in other 
species (mouse, bovine or rhesus monkey).
Figure 1. Gene ontology (GO) processes and the pathways most strongly enriched among endometrial 
receptivity-associated genes. Genes are presented on the right side on the circle and the correlating GO 
processes, cellular compartments and pathways are on the left side.
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Validation analysis of predicted microRNAs and target mRNAs in independent sample set. In 
silico analysis of potential microRNAs regulating the meta-signature genes predicted interactions between 30 
meta-signature genes and 348 microRNAs. Using the list of the predicted interactions, we investigated if these 
potentially interacting microRNAs are significantly regulated in our endometrial microRNA-sequencing data on 
endometrial biopsies from the mid-secretory phase vs. early secretory phase of healthy fertile women. We identi-
fied 19 microRNAs that were significantly down-regulated in the mid-secretory endometria with corresponding 
11 meta-signature genes to be significantly up-regulated in our sample set (Fig. 6). Based on the TargetScan 
context++ scores, the probability of the interaction between microRNA and its target gene seems to be higher in 
pairs miR-449c-5p and DKK1, miR-450b-5p, miR-424-5p, miR-130b-3p and IL15, miR-500a-5p and GADD45A, 
and miR-181a-2-3p and ACADSB. When focussing only on the genes that were confirmed in both independent 
validation analyses (RNA-seq of endometrial biopsies and cell type-specific RNA-seq), five target genes (ANXA4, 
ARID5B, DKK1, EFNA1 and SPP1) and 10 microRNAs remained important (Fig. 6).
Figure 2. Schematic overview of the 57 meta-signature genes, their literature-based localisation and 
involvement in the mid-secretory phase endometrium. Different membrane-associated proteins (ABCC3, 
ANXA2, ANXA4, AQP3, CD55, DKK1, DPP4, EDN3, EDNRB, EFNA1, ENPEP, SFRP4, SLC1A1, SPP1, 
TSPAN8), epithelial cell tight junction protein (CLDN4), secreted enzymes and binding proteins (APOD, CP, 
GPX3, IGFBP1, TCN1), secreted immune response proteins (DEFB1, GLNY, IL15, PAEP), extracellular matrix-
associated proteins (COMP, HABP2, LAMB3, MMP7), different enzymes (ACADSB, AOX1, ARG2, IDO1, 
MAOA, NNMT), signalling proteins (C10orf10, GBP2, G0S2, MAP3K5, NDRG1), metallothioneins (MT1G, 
MT1H), DNA binding and repair proteins (ARID5B, DDX52, GADD45A), transcription factors (BCL6, 
CEBPD, ID4), and other intracellular proteins (CRABP2, DYNLT3, OLFM1, PRUNE2, S100P) are indicated. 
Additionally, the enriched KEGG pathway of complement cascade with the identified genes C1R, SERPING1, 
CD55, C4BPA and CFD is highlighted. (Figure created by Elsevier Illustration Service).
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Discussion
In this report, we present a systematic review and meta-analysis approach together with comprehensive experi-
mental validation in order to identify promising biomarkers and molecular pathways involved in mid-secretory 
endometrial functions. Analysing the lists of differentially expressed genes from previously published expression 
profiling studies, we established a meta-signature of receptive endometrium with 57 genes as putative receptiv-
ity biomarkers. Interestingly, the commercial transcriptome-based endometrial receptivity diagnostic tool ERA 
(Endometrial Receptivity Array)7, 30 shares 47 genes in common with the identified meta-signature. Validation of 
the meta-signature genes in two different sample sets of healthy fertile women in mid-secretory vs. early secretory 
endometria using the up-to-date transcriptome analysis by RNA-seq confirmed 39 meta-signature genes.
The human endometrial transcriptome has been extensively studied in the past decade in a search of identi-
fying diagnostic markers of receptive endometrium and to provide more understanding into the complex reg-
ulation of endometrial functions. Despite of the mass ‘omics’ data generated, only three in silico data-mining 
studies17, 31, 32 using previously published gene expression data have been published to date. Bhagwat et al. created 
a Human Gene Expression Endometrial Receptivity database (HGEx-ERdb) of 19,285 genes expressed in human 
endometrium, among which they identified 179 receptivity-associated genes32. Zhang et al. analysed raw data 
from three previous microarray studies33–35 and proposed 148 potential biomarkers of receptive endometrium17, 
while Tapia et al. integrated gene lists from seven previous microarray studies and presented a list of 61 endome-
trial receptivity biomarkers31. These three in silico analysis studies share only nine genes in common, highlighting 
the differences not only in in silico analysis approaches applied but also the great variation in study designs, anal-
ysis methods and data processing in published transcriptome studies. Clearly the mass of data generated within 
endometrial transcriptomics studies is under-explored, challenging investigators in future to analyse huge sets of 
data simultaneously in order to raise power, credibility and reliability of the findings.
The preferred method for gene expression meta-analysis requires analysis of raw expression datasets. However, 
such a thorough analysis is often not possible as a result of unavailability of raw data, which is partially the case 
in our meta-analysis. Variation in the number of gene transcripts known at a given moment together with the 
Figure 3. Extracellular vesicles (EVs) – exosomes and microvesicles, in embryo-endometrium cross-talk. In the 
exosomes the meta-signature genes are highlighted (based on ExoCarta database). Exosomes (30–100 nm) are 
generated from inward budding of the endosomal membrane, resulting in formation of a multivesicular body. 
Microvesicles (100 nm–1 μm) are produced by direct budding of the plasma membrane. Membrane-associated 
(bubbles) and transmembrane proteins (cylinders), and nucleic acids (DNA, RNA, curved symbols) are 
selectively incorporated into the EVs. EVs may dock on the plasma membrane of a target cell (A), fuse directly 
with the plasma membrane (B), or be endocytosed (C). Endocytosed vesicles may subsequently fuse with the 
delimiting membrane of an endocytic compartment (D). Both (B and D) pathways result in the delivery of 
proteins and nucleic acids into the membrane or cytosol of the target cell. (Figure adapted with permission 
from62, 84, created by Elsevier Illustration Service).
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technological platform employed makes proper integration of raw datasets complicated. In addition, the limited 
sample size and noisiness of microarray data have resulted in inconsistency of biological conclusions36. In order 
to overcome these limitations, we directly analysed lists of differentially expressed genes from nine published 
studies involving a total of 164 endometrial biopsy samples from healthy women. Using a method that has been 
specifically designed for comparison of gene lists and identification of commonly overlapping genes in various 
studies, including recently published transcriptome studies in different ethnic groups30, 37, 38, we hope to provide 
an up-to-date meta-signature of endometrial receptivity biomarkers. Nevertheless, we have to bear in mind that 
with our approach, analysing the significantly differentially expressed gene lists, we could have missed the poten-
tial biomarker genes that were below statistical significance in individual studies but could become relevant in a 
meta-analysis.
The 57 genes identified in our meta-analysis could serve as the top-priority biomarkers of receptive phase 
endometrium in humans. Of special interest is SPP1, which was detected in all transcriptome studies that were 
included in our meta-analysis, together with ANXA4, CLDN4, DPP4, GPX3, MAOA, and PAEP, as they have 
also been identified as putative biomarkers of endometrial receptivity in the previous data-mining and review 
studies17, 19, 29, 31, 32.
Secreted phosphoprotein 1, SPP1, also known as osteopontin, is a secreted extracellular matrix (ECM) protein 
that binds to different cell-surface integrins to stimulate cell–cell and cell–ECM adhesion and communication 
(see Fig. 2), which play a part in the implantation process in various species39–41. It is generally accepted that SPP1 
interacts with apically expressed integrins on the luminal endometrial epithelium and embryo trophectoderm to 
attach the conceptus to the endometrium39. Indeed, our cell type-specific RNA-seq validation analysis of endo-
metrial epithelial and stromal cells demonstrates that SPP1 is up-regulated only in the epithelial cells (though in 
our setting we had a mixture of both luminal and glandular epithelial cells) and not in the stromal cells in the 
receptive phase endometrium (Fig. 5). Dysregulation of osteopontin in mid-secretory endometria of women with 
various reproductive disorders has been detected in several studies42–46. Further, our previous systems biology 
approach in investigation of the molecular networks in the implantation process revealed the involvement of 
osteopontin together with leukemia inhibitory factor (LIF), apolipoprotein D (APOD) and leptin (LEP) pathways 
intertwining in a large network of cytokine–cytokine receptor interactions37.
Our meta-signature of mid-secretory endometrium highlights the importance of defence responses, 
specifically the inflammatory response (now recognized as a type of non-specific immune response), 
immunoglobulin-mediated immune responses (humoral immunity) and the complement (major mediator 
of innate immunity), and coagulation cascade pathway in receptive-phase endometrium. Immune responses, 
including the inflammatory response, play important roles in the pre- and peri-implantation period, and the 
up-regulation of genes involved in immune responses during the mid-secretory phase was corroborated in our 
meta-analysis and has also been highlighted in several previous studies20, 31, 47–49. In order to provide a hospitable 
environment for the embryo, the balance should be established between the maternal immune tolerance toward 
a semi-allogeneic implanting embryo and the protective anti-infectious mechanisms in the receptive-phase 
Figure 4. Validation of the meta-signature genes in two independent sample sets. RNA-seq analysis of 
endometrial tissue samples confirmed differential expression of 52 (91.2%) meta-signature genes in the mid-
secretory phase endometrium vs. early secretory phase endometrium. Cell type-specific RNA-seq analysis of 
endometrial epithelial and stromal cells confirmed differential expression of 43 (75.4%) meta-signature genes in 
those cell populations in the mid-secretory endometrium vs. early secretory endometrium. In total, 39 (68.4%) 
meta-signature genes (typed in white colour) were identified in validation experiments on two different sample 
sets, where 35 genes were up-regulated and 4 genes (CRABP2, EDN3, OLFM1, SFRP4) down-regulated in the 
mid-secretory phase endometrium.
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uterus47, 49. The innate immune system is the first line of defence, providing an immediate response through 
its ability to distinguish between ‘infectious non-self ’ and ‘non-infectious self ’ antigens50. Our meta-analysis 
highlights the importance of five genes involved in innate immunity, specifically in the complement system in 
mid-secretory endometrium, i.e. C1R, SERPING1, CD55, C4BPA and CFD, as shown in Fig. 2. CD55 (also known 
as DAF), for instance, is a complement regulatory protein with two suggested functions: protection of the embryo 
from maternal complement-mediated attack, and prevention of epithelial destruction resulting from increased 
complement expression at the time of implantation51. This protein has been found to be expressed at decreased 
levels in the endometria of women with recurrent pregnancy loss with antiphospholipid syndrome52. C4BPA is 
also suggested to have an embryo-protective role, where increased expression of this inhibitor of complement 
system activation could reduce the possibility of an uncontrolled complement attack on embryo31. Abnormally 
decreased levels of C4BPA expression in mid-secretory phase endometrium have been detected among women 
with endometriosis53, 54, implantation failure55 and unexplained recurrent abortion56.
The finding that a significant proportion of meta-signature genes are located in extracellular regions, including 
extracellular vesicles/exosomes, is intriguing. It is well known that the luminal epithelium with its extracellular 
area is the first maternal surface to interact with the trophoblast cells of the implanting embryo, but the involve-
ment of extracellular vesicles in the implantation process is a new phenomenon57–61. Extracellular vesicles are 
membrane-bound complexes secreted from cells that act as messengers for cell–cell communication and signal-
ling62. The origin of microvesicles and exosomes from endometrial epithelial cells in mid-secretory endometrium, 
the involvement of endometrial receptivity genes/proteins in exosomes and the uptake of extracellular vesicles 
by target blastocyst cells is depicted on Fig. 3. It has been proposed that extracellular vesicles, containing spe-
cific RNAs, including microRNAs and proteins, are released into the uterine cavity that could be transferred to 
either trophoblast cells or to endometrial epithelial cells, where they promote implantation57, 58, 62, 63. Twenty eight 
proteins from our endometrial receptivity-associated gene list have been experimentally detected in exosomes 
in humans (ExoCarta database). Our findings support the role of exosomes in endometrial receptivity and the 
subsequent embryo implantation, and indicate that further research into functional effects of extracellular ves-
icles in embryo-endometrium cross-talk is needed. Research on extracellular vesicles is a rapidly evolving and 
expanding field that could offer new opportunities regarding biomarkers of receptive endometrium and embryo 
implantation. Especially intriguing is the fact that extracellular vesicles have the potential in the development of 
non-invasive biomarkers and for thriving novel therapies to increase reproductive success.
Figure 5. Validation of the meta-signature genes on cell type-specific RNA-seq data. Significantly up-regulated 
(orange) and down-regulated (blue) genes in FACS-sorted stromal and epithelial cells. The x-scale represents 
log2(FC) between LH+8 vs. LH+2 comparisons in stromal and epithelial cells. When comparing the gene 
expression values between epithelial vs. stromal cells in the mid-secretory phase endometrium (LH+8), most 
genes were more up-regulated in the epithelial cells (higher expression highlighted as darker orange). All 
reported results are significant at FDR < 0.05.
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The involvement of microRNAs in the mid-secretory endometrial functions has been shown by previous 
studies18. Further, studies on mice demonstrate that microRNAs are important in implantation and pregnancy, 
and the loss of Dicer (RNAse III endonuclease that is essential for the biogenesis of microRNAs) within uterus 
can compromise fertility64. MicroRNAs are non-coding RNA molecules acting as posttranscriptional regulators 
of gene expression and operate by either degrading or translationally repressing the target mRNAs65. There are 
now known over 2,000 annotated microRNAs in the human genome66, and since each microRNA may regulate 
hundreds of genes, it is estimated that microRNAs collectively regulate one third of genes in the genome67. Our 
prediction and subsequent validation analyses identified 19 down-regulated microRNAs in the mid-secretory 
phase endometria that resulted in up-regulation of 11 target mRNAs, because of reduced miRNA-mediated 
repression. Of special interest are miR-130b-3p and ANXA4, miR-548n and SPP1, miR-548ah-3p, miR-30c-1-3p 
and EFNA1, miR-30c-1-3p and ARID5B, and miR-449c-5p and DKK1 pairs, where the meta-signature gene was 
validated in two independent validation analyses. The importance of miR-30 family members, miR-30b and miR-
30d, in endometrial receptivity have been highlighted in different studies58, 68–70, however the changed expression 
of miR-30c-1 has been detected so far in endometrial cancer patients71. In porcine endometrium the expression 
of miR-30c has been shown to increase during the gestational days, meaning that at the time of implantation this 
microRNA has been down-regulated when compared to placentation and mid-gestational times72. The increased 
expression of miR-130b and miR-449c-5p have been detected in endometrial cancer patients when compared to 
controls73, 74.
With our meta-analysis we highlight highly potential biomarkers of endometrial receptivity, but their molec-
ular mechanisms in uterine physiology and pathophysiology remain to be investigated. Furthermore, to our 
knowledge, none of the molecular markers have yet been successfully applied in clinical therapeutic practice, 
including the highly promising molecule LIF15. Hence, the hunt for potentially informative and therapeutic mark-
ers of uterine receptivity continues. The era of looking for endometrial receptivity markers at other ‘omics’ levels 
has begun and it is to be hoped that this will result in further promising results (reviewed by refs 18 and 75). We 
believe that a novel approach for the future could hold in the microRNAs and/or exosome-based testing and 
therapeutic strategy for improving endometrial receptivity. Regardless of the biomarker sets chosen to identify 
receptive endometrium, all will need extensive validation before their clinical utility can be proven. Several of our 
meta-signature genes have already been validated on mRNA and/or protein level in individual marker and/or 
transcriptome studies (summarised in Table 2).
In conclusion, we present a meta-analysis approach allowing convergence and dissection of heterogene-
ous mRNA expression profiling datasets of receptive phase endometrium. We identified a meta-signature of 
Figure 6. In silico predicted interactions between significantly up-regulated mRNAs (red) and down-regulated 
microRNAs (green) in LH+8 vs. LH+2 endometrium. The colour intensity indicates the strength of up- or 
down-regulation (FDR < 0.05). The colour of the arrows between the microRNA and mRNA represents 
TargetScan context++ score (see Supplementary Table 2 for scores), where darker arrow shows more probable 
interaction. The number of arrows between microRNA and mRNA indicates different microRNA binding sites 
within the same transcript. Meta-signature genes that were confirmed in both independent validation analyses 
together with their corresponding miRNAs are highlighted with black circle/diamond borders.
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endometrial receptivity composed of 57 genes, where 39 of these genes were experimentally confirmed in two 
separate datasets. These meta-signature genes highlight the importance of immune responses, the complement 
cascade pathway and the involvement of exosomes in mid-secretory endometrial functions, and could serve as 
promising biomarkers of endometrial receptivity and achieving a pregnancy.
Methods
Systematic search of the literature. A systematic review of the literature in PubMed and Scopus was 
independently conducted up to June 2016 by two researchers (S.A. and M.S.). MeSH terms ‘embryo implantation’, 
‘endometrium’ and ‘gene expression’ were used. The reference lists of review articles and relevant studies were 
hand-searched to identify other potentially eligible studies. No language or any other restrictions were applied. 
Details of the protocol for this systematic review were registered on PROSPERO and can be accessed at: http://
www.crd.york.ac.uk/PROSPERO/display_record.asp?ID = CRD42016041509.
Abstracts of all articles identified through the search were read for selection of eligible studies. The full text 
of each eligible article was carefully evaluated. Only original experimental studies published in English and con-
cerning the endometrial transcriptome (using microarray or RNA-seq techniques) in healthy women in the 
mid-secretory phase vs. the ‘pre-receptive’ phase (proliferative and/or early secretory phase) were included for 
final analysis. Endometrial transcriptome analysis in connection with any pathological condition, such as infer-
tility, endometriosis, adenomyosis and cancer was excluded. In addition, transcriptome analyses focussing on 
different endometrial tissue-compartments separately were not included in the meta-analysis.
Analysis settings. The lists of genes differentially expressed in mid-secretory vs. ‘pre-receptive’-phase 
endometrium were extracted from the publications. Where the gene lists were not available, the authors were 
contacted directly. In transcriptome array studies, if the probe information for a dataset was available, probes 
were annotated to corresponding ENTREZ IDs using respective Bioconductor 3.1 Affymetrix probe annotation 
package, in studies using Affymetrix microarray platform. If probe-level data was not available, gene lists were 
converted to ENTREZ IDs by using the DAVID Gene ID Conversion Tool (DAVID Bioinformatics Resources). 
Genes reported in a study by Hu et al. that involved Illumina RNA-seq platform38 were standardised to ENTREZ 
IDs by using the BiomaRt package and ENSEMBL v.75 database. For one study33, the differentially expressed 
probe lists were acquired by reanalysing the data stored in the Gene Expression Omnibus under accession num-
ber GSE6364. We used GEO2R web tool (http://www.ncbi.nlm.nih.gov/geo/info/geo2r.html) with default options 
for differential analysis and gene list acquisition (false discovery rate, FDR < 0.05; fold change, FC > 2.0). Probes 
not annotated by ENTREZ IDs were removed from subsequent analyses.
Subsequently, lists of up- and down-regulated genes were ranked by their fold changes. In cases of multiple 
probes detecting the same gene, only the probe with the largest absolute fold change was used for list construction.
Meta-analysis. The robust rank aggregation algorithm (RRA package v.1.1) was used for meta-analysis of 
the ranked gene lists24. To assess full gene list sizes, the number of detectable gene ENTREZ IDs was used for 
each array platform and all ENTREZ IDs from BioMart v.75 were used for the RNA-seq study38. For correcting 
for multiple testing, we used a strict Bonferroni threshold by multiplying all P-values by the maximal number of 
elements in all input lists. In our case this involved the data published by Hu et al.38, where the total number of 
ENTREZ IDs available in ENSEMBL v.75 (39,030) was used as the total number of tests. All lists used in the anal-
ysis reflect expression in the mid-secretory group compared with another group (proliferative or early-secretory 
phase).
Enrichment analysis. Enrichment analyses for Gene Ontology (GO) terms and biological pathways (KEGG 
and Reactome) were carried out by using the g:Profiler web tool (biit.cs.ut.ee/gprofiler/)76, 77. This software was 
chosen over other enrichment analysis tools as it is up-to-date (updated in May 2016 to Ensembl 84 and Ensembl 
Genomes 31) and it provides a compact graphical output. The obtained results were corrected for multiple testing 
by using the g:Profiler tailor-made algorithm g:SCS, which has been shown to provide a better threshold between 
significant and non-significant results than (commonly used) Bonferroni correction or the Benjamini-Hochberg 
false discovery rate76.
In silico analysis of potential microRNAs regulating meta-signature genes. MicroRNA target 
prediction was performed using three different algorithms – DIANA microT-CDS, TargetScan 7.0 and miRanda 
v3.3a. In DIANA microT-CDS78 and TargetScan 7.079 precomputed prediction results were downloaded from 
their respective websites (diana.imis.athena-innovation.gr/DianaTools/index.php?r = microT_CDS/index; www.
targetscan.org/cgi-bin/targetscan/data_download.cgi?db = vert_70). DIANA microT-CDS utilises ENSEMBL 
v69 transcriptome and miRBase v18 for the prediction, whereas TargetScan 7.0 uses ENSEMBL v75 and miRBase 
v2180. miRanda v3.3a binary81 was downloaded from http://www.microrna.org/microrna/getDownloads.do and 
used for the target prediction with ENSEMBL v75 3′UTRs and miRBase v21 mature sequences as an input. The 
algorithm was used with default settings: Gap Open Penalty: −9.0, Gap Extend Penalty: −4.0, Score Threshold: 
140.0, Energy Threshold: 1.0 kcal/mol and Scaling Parameter: 4.0. miRBase internal IDs were used to standardise 
microRNA names between different miRBase versions.
For additional support to in silico target predictions, we used database harbouring experimental data about 
mammalian microRNA binding sites. Therefore, Argonaute (AGO1, AGO2, AGO3 and AGO4) HITS-CLIP and 
PAR-CLIP datasets for human cell lines were downloaded from StarBase v.2.082 website in the BED format and 
overlaid with predicted microRNA target sites (http://starbase.sysu.edu.cn/download.php).
Validation of meta-signature genes and predicted microRNAs in the independent sample 
sets. We validated the meta-signature genes in our two independent sample sets from NOTED project 
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(EU-FP7 Eurostars Programme, EU41564) and SARM project (EU-FP7, IAPP, EU324509). The studies were 
approved by the local Research Ethics Committees of the University of Tartu and Instituto Valenciano de 
Infertilidad. An informed consent was signed by all women who agreed to participate in the study, and all meth-
ods were carried out in accordance with relevant guidelines and regulations.
The detailed description of the study participants and RNA-seq analysis within NOTED project is described 
in the Supplementary Material. Briefly, 20 healthy fertile women provided endometrial biopsy samples in the 
early secretory phase (2 days after the luteinizing hormone (LH) peak, LH+2) and in the mid-secretory phase of 
the menstrual cycle (LH+8) within the same natural cycle. Total mRNA transcriptome and microRNA profile 
analysis from the same biopsy samples were performed with the RNA-seq method. Differential expression was 
tested using the edgeR statistical package. Up-regulation was defined as statistically significantly (FDR corrected 
p-value < 0.05) higher expression (expressed as ‘counts per million reads’, CPM) in the mid-secretory phase sam-
ples, whereas down-regulation was defined as statistically significantly lower expression in the mid-secretory 
samples. The primary RNA-seq data are available in the public database Gene Expression Omnibus (www.ncbi.
nlm.nih.gov/geo/) under accession number GSE98386.
The other independent set of validation was carried out in additional 16 healthy fertile women within SARM 
project, where cell type-specific RNA-seq on endometrial samples was performed, with separated epithelial and 
stromal cells. Briefly, endometrial biopsies were collected from 16 healthy fertile women on two different time 
points within the natural cycle, LH+2 and LH+8. Single cells from endometrial biopsy samples were separated, 
epithelial cells were labelled with fluorochrome-conjugated mouse anti-human CD9 monoclonal antibody and 
stromal cells were simultaneously labelled with fluorochrome-conjugated mouse anti-human CD13 monoclo-
nal antibody, followed by flow cytometric analysis and FACS cell sorting. Bulk-RNA full transcriptome analysis 
of FACS sorted endometrial epithelial and stromal cells was performed with the RNA-seq method, following 
the single-cell tagged reverse transcription (STRT) protocol with modifications83. Differential expression was 
tested using the edgeR statistical package. Up-regulation was defined as statistically significantly (FDR corrected 
p-value < 0.05) higher expression (expressed as ‘normalised read counts’) in the mid-secretory phase samples, 
whereas down-regulation was defined as statistically significantly lower expression in the mid-secretory samples. 
The primary RNA-seq data are available in the public database Gene Expression Omnibus (www.ncbi.nlm.nih.
gov/geo/) under accession number GSE97929. Detailed protocol of the sample collection, processing, and analy-
sis is described in the Supplementary Material.
Further validation of the endometrial receptivity signature genes DDX52, DYNLT3, C1R and APOD on 
NOTED and SARM project samples using real-time PCR is described in the Supplementary Material.
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